Current antiretroviral therapy (ART) for HIV / AIDS can suppress replication of the virus to undetectable levels, and infected people can live without symptoms for as long as possible. However, discontinuation of therapy provides rapid re-emergence of the virus from a very stable reservoir of latently infected cellulose which constitutes a barrier to the current ART infection. Two prospective cohorts of HIV infection are promoted by two casual fortunes in which individuals have been admitted to remodeling stem cells from compatible donors resistant to HIV. However, the development of a routine remedy that could infect infected individuals will require that the cells harboring latent HIV. Editing genes by the latent provirus or the destruction of the provirus genomes. The elimination of latently infected cells may require a means of exposing this population, which may involve the identification of a specific natural biomarker or a therapeutic intervention force that is responsible for the expression of the virus. Consequently, the proposed "Shock and Kill" strategy may be used to treat latency reversing agents (LRAs) with therapeutic expression of HIV provirus, thereby exposing these cells to destruction of cellular immunity or apoptosis. Current efforts to enable this strategy include a broad and robust induction of LRAs to produce a broad and robust induction of HIV provirus and elimination of cells where replication has been reactivated by uniblization modulation. Alternative strategies include the "lock and block" interference of cells that are latently infected by a laser prevention of reversible virus, where the transcription of the provirus is inhibited by the virus that causes the virus to spread and the virus is then edited by the HIV provirus.